NCT03710811Unknown不适用
Observational Study of Drug Naive Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2017年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Circulating immunity cell profiles
研究概览
简要总结
A multi-centre, open-label trial to investigate the efficacy and possible mechanism of Continuous Subcutaneous Insulin Infusion treatment in patients with drug naive type 2 diabetes.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •for type 2 diabetes:
- •Male or female age ≧ 25 years and ≦75 years old
- •HbA1c ≧8.0%
- •for normal controls：
- •Male or female age ≧ 25 years and ≦75 years old
- •Normal glucose tolerance confirmed by oral glucose tolerance test
排除标准
- •Islet antibody positive
- •Athletes, has a history of skeletal muscle injury ( trauma or surgery ), skeletal muscle wasting diseases ( such as mitochondrial myopathy, muscular atrophy, etc )
- •Acute infection(such as cute upper respiratory infection, acute pneumonia)
- •long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs
- •consists with other endocrine diseases
- •use of antibiotics in 3 months
- •chronic digestive inflammations
- •magnetic resonance imaging contraindications
研究组 & 干预措施
Type 2 Diabetes
drug naive Type 2 Diabetes received insulin therapy
干预措施: Insulin (Drug)
结局指标
主要结局
Circulating immunity cell profiles
时间窗: 7 days
profiles of circulating immunity cells such as T cells
次要结局
- skeletal muscle parameter(7 days)
研究者
Dalong Zhu
Doctor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and EndocrinologistsType 2 Diabetes MellitusNCT03209089AstraZeneca907
已完成
不适用
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)Type 2 Diabetes MellitusNCT01357135Merck Sharp & Dohme LLC3,453
已完成
1 期
In-patient Study in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00259896GlaxoSmithKline30
已完成
3 期
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)Type 2 Diabetes Mellitus, Non Insulin DependentDiabetes Mellitus, Non-Insulin-DependentNCT00701090Merck Sharp & Dohme LLC1,035
已完成
不适用
Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients.Type 2 DiabetesNCT04745780Lo.Li.Pharma s.r.l75